Pharmaceutical Knowledge-Capital Accumulation and Longevity

Frank R. Lichtenberg

in Measuring Capital in the New Economy

Published by University of Chicago Press

Published in print October 2005 | ISBN: 9780226116129
Published online February 2013 | e-ISBN: 9780226116174 | DOI:
Pharmaceutical Knowledge-Capital Accumulation and Longevity

More Like This

Show all results sharing this subject:

  • Econometrics and Mathematical Economics


Show Summary Details


This chapter evaluates the contribution of pharmaceutical research and development (R&D) to longevity increase by analyzing the relationship between Food and Drug Administration (FDA) approvals of new molecular entities and changes in the age distribution of deaths from all diseases, using longitudinal disease-level data. It explains the measurement of pharmaceutical knowledge-capital accumulation and proposes an econometric model of the effect of pharmaceutical knowledge-capital accumulation on the age distribution of deaths. The findings reveal that the estimates indicated that approval of standard-review drugs has no effect on longevity, but that approval of priority-review drugs has a significant positive impact on longevity.

Keywords: pharmaceutical R&D; longevity increase; FDA; new molecular entities; age distribution; knowledge-capital accumulation; econometric model; priority-review drugs; longevity

Chapter.  13774 words.  Illustrated.

Subjects: Econometrics and Mathematical Economics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.